Cover Image
市場調查報告書

癌症免疫疾病學和腫瘤溶解性病毒學:技術和全球市場

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

出版商 BCC Research 商品編碼 298488
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
癌症免疫疾病學和腫瘤溶解性病毒學:技術和全球市場 Cancer Immunology and Oncolytic Virology: Technologies and Global Markets
出版日期: 2014年03月28日 內容資訊: 英文 106 Pages
簡介

免疫疾病學為基礎的癌症治療方法,是近幾年重新開發的技術,在創新的新藥需求高漲中急速發展。全球癌症免疫疾病療法市場上的銷售額,預計將從2012年的308億美元擴大到2018年的689億美元,其間年平均成長率為14.7%。

本報告提供癌症免疫疾病療法的全球市場概觀,從2012年和13年的資料進行全世界的市場趨勢分析,以及至2018年的預測、影響臨床指南和人口組成的變化、市場成熟度等需求的要素和包含專利的技術方面分析,加上主要製造商的簡介等,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 癌症免疫疾病學的歷史和現狀
    • 癌症的類型
    • 癌症治療的類型
      • 手術
      • 放射線治療
      • 藥物治療
      • 免疫疾病療法
      • 發炎反應
    • 癌症治療困難的理由
    • 對臨床性重要的癌症
      • 前列腺癌症
      • 慢性淋巴球性白血病(CLL)
      • 乳癌
      • 轉移性黑色素瘤
      • 卵巢癌症
      • 子宮頸癌症
      • 頭頸部癌症
      • 肺癌症
      • 腦瘤
      • 多發性骨髓瘤
      • 胰臟癌症
  • 到2018年的全世界癌症趨勢相關摘要
  • 成為癌症進展原因的可能性高的環境
    • 遺傳
    • 暴露放射線
    • 暴露於化學性致癌物質
    • 暴露於生物性致癌物質
  • 人類癌症相關研究開發

第4章 癌症免疫疾病療法概要

  • 作用機制
    • 人類免疫疾病系統
    • T細胞
    • PD-1及PD-L1抑制劑
  • 生物反應調節劑
    • 細胞聚落刺激因子
    • 干擾素(interferon)
    • 白細胞介素產品
    • 治療用單株抗體
  • 癌症疫苗
    • 防禦癌症的疫苗
    • 治療用癌症疫苗
      • 黑色素瘤(Melanoma)
      • 乳癌
      • 子宮頸癌症
      • 卵巢癌症
      • 腎細胞癌症
      • 肺癌症
      • 胰臟癌症
      • 前列腺癌症
  • 癌症治療的其他免疫疾病療法產品
    • GLEEVEC
    • IRESSA
    • KYPROLIS
    • NEXAVAR
    • POMALYST
    • SUTENT
    • TARCEVA
    • TYKERB
    • VELCADE
  • 部分臨床試驗階段的醫藥品相關補充資訊

第5章 腫瘤溶解性病毒療法

  • 病毒療法
  • 腫瘤溶解性病毒學
    • HIV對癌症治療的應用
    • 利用病毒的兒童癌症治療
    • 腫瘤溶解性病毒學領域的企業動向
  • 癌症免疫疾病療法和病毒學領域的新聞與契約
  • 各國政府的法規
  • 產業結構
  • 關乎腫瘤溶解性病毒研究的企業

第6章 主要市場

  • 腫瘤溶解性病毒產品的市場

第7章 技術

  • 單株抗體的生產
    • 抗體藥物複合體
    • 嵌合抗原受體(CAR)表達T細胞技術
  • 專利的評估
    • 加拿大的單株抗體技術
    • 印度的智慧財產權保護問題
    • 重新發行的專利

第8章 主要企業簡介

  • ABLYNX NV
  • ADURO BIOTECH, INC.
  • ADVAXIS INC.
  • ASTRAZENECA U.S.
  • BRISTOL-MYERS SQUIBB
  • CELGENE CORP.
  • DENDREON CORP.
  • DNATRIX, INC.
  • GENENTECH, A MEMBER OF THE ROCHE GROUP
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE, INC.
  • IMMATICS BIOTECHNOLOGIES GMBH
  • IMMUNOMEDICS, INC.
  • IMMUNOVACCINE, INC.
  • JANSSEN BIOTECH INC./JOHNSON & JOHNSON
  • JENNEREX BIOTHERAPEUTICS INC.
  • MEDIMMUNE LLC (ASTRAZENECA)
  • MEDIVATION INC.
  • MERCK & CO.
  • NORTHWEST BIOTHERAPEUTICS, INC.
  • NOVARTIS INTERNATIONAL AG
  • NOVARTIS PHARMACEUTICALS CORP.
  • ONCOMED PHARMACEUTICALS INC.
  • PFIZER INC.
  • ROCHE (F. HOFFMAN-LA ROCHE AG)
  • VIRALYTICS, LTD.

圖表清單

目錄
Product Code: PHM129A

The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.

This report provides:

  • An overview of the global market for cancer immunotherapies
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.
  • Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturation
  • Technological discussion including the current state, newly issued patents, and pending applications
  • Profiles of leading companies in the industry.

STUDY GOALS AND OBJECTIVES

This report, PHM129A Cancer Immunology and Oncolytic Virology: Technologies and Global Markets provides an overview of the current and potential global market for cancer immunotherapy and virology. The report provides comprehensive information on a number of the most common cancers, highlighting global incidence and prevalence. It identifies the need for more effective drugs for treatment of these diseases. The key objective is to present a comprehensive analysis of the current state of cancer immunotherapy and where this field is going. A second objective is to examine the current state of oncolytic virology and where this nascent field appears to be heading. Important trends in each field, clinical trials and results, new developments and sales forecasts for cancer immunotherapy from 2011 through 2018 are provided in this report. In addition, sales forecasts are presented for oncolytic virology covering the years 2011 through 2023. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the cancer market. The report also addresses opportunities for future players.

REASONS FOR DOING THE STUDY

This study was conducted to provide detailed information regarding the new area of immunology-based treatment options for cancer. There is an increasing need for new and innovative drugs. This young industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer, more efficacious treatment strategies. This study looks at the latest types of treatment strategies based on immunology, as well as the new field of oncolytic virotherapy, a field still in its infancy showing immense promise for the clinical management of cancer.

This BCC Research market research report will increase the reader's awareness of current and emerging drugs and technologies for many cancers.

SCOPE OF REPORT

The scope of this study entails the current immunology therapeutics markets for several of the most common cancers. The sectors covered are colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines and other cancer treatment immunology products. Vaccines against HPV and hepatitis B are included; while such vaccines act only indirectly against cancer, they do serve to protect against the disease. Also covered is oncolytic virology, so new that its market tables have been presented separately from the immunotherapy tables. The report also includes discussion of the regulatory environment, current and developing technologies, cancer incidence, market projections and market share, along with latest trends and clinical trials.

ANALYST CREDENTIALS

Valerie Kellogg is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from treatment of obesity to ablation devices, from wound care to treatment of chronic migraine. Her strong focus areas include treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • HISTORY AND CURRENT STATE OF CANCER IMMUNOLOGY
    • CANCER TYPES
    • TYPES OF CANCER TREATMENT
      • Surgery
      • Radiation Therapy
      • Pharmaceutical Therapy
      • Immunotherapy
      • Inflammatory Response
    • WHY IS CANCER SO DIFFICULT TO CURE?
      • Treatment-resistant Cancer
      • Strategies to Improve Response and Decrease Mortality
      • Pre-emptive Therapy
      • Early Stage vs. Advanced Cancer
    • MOST CLINICALLY SIGNIFICANT HUMAN CANCERS
      • Prostate Cancer
        • TABLE 1: GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012
      • Diagnosis
      • Treatment
      • Prognosis
      • Chronic Lymphocytic Leukemia (CLL)
        • TABLE 2: GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012
      • Diagnosis
      • Treatment
      • Prognosis
      • Breast Cancer
        • TABLE 3: GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
        • TABLE 4: BREAST CANCER INCIDENCE, 2012 (NUMBER)
      • Diagnosis
      • Treatment
      • Prognosis
        • TABLE 5: PROGNOSIS OF BREAST CANCER BASED UPON STAGE (%)
      • Metastatic Melanoma
        • TABLE 6: GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
      • Diagnosis
      • Treatment
      • Prognosis
      • Ovarian Cancer
        • TABLE 7: GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
      • Diagnosis
      • Treatment
      • Prognosis
        • TABLE 8: RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCER (%)
      • Cervical Cancer
        • TABLE 9: GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
      • Diagnosis
      • Treatment
        • TABLE 10: AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • Prognosis
        • TABLE 11: FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSIS (%)
      • Head and Neck Cancer
        • Diagnosis
        • Treatment
        • Prognosis
      • Lung Cancer
        • TABLE 12: GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
        • TABLE 13: STAGES OF LUNG CANCER
      • Treatment
      • Prognosis
        • TABLE 14: NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGE (%)
      • Brain Cancer
        • TABLE 15: GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
      • Treatment
      • Prognosis
      • Multiple Myeloma
        • TABLE 16: GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
      • Treatment
      • Prognosis
      • Pancreatic Cancer
        • TABLE 17: GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
      • Diagnosis
      • Treatment
      • Prognosis
        • TABLE 18: EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATE (%)
  • SUMMARY OF GLOBAL HUMAN CANCER TRENDS THROUGH 2018
    • TABLE 19: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • FIGURE 1: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 20: U.S. HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 21: CANADIAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 22: EUROPEAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 23: JAPANESE HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 24: REST OF WORLD HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
  • CIRCUMSTANCES MOST LIKELY TO LEAD TO ADVANCED CANCERS
    • Genetics
    • Exposure to Radiation
    • Exposure to a Chemical Carcinogen
      • TABLE 25: KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCER
    • Exposure to a Biological Carcinogen
  • HUMAN CANCER R&D

CHAPTER 4 - OVERVIEW OF CANCER IMMUNOTHERAPY

  • MECHANISMS OF ACTION
    • HUMAN IMMUNE SYSTEM
    • T CELLS
    • PD-1 AND PD-L1 BLOCKERS
  • BIOLOGICAL RESPONSE MODIFIERS
    • COLONY-STIMULATING FACTORS
      • TABLE 26: COLONY-STIMULATING FACTORS ON THE MARKET
    • INTERFERONS
      • TABLE 27: SELECTED INTERFERON PRODUCTS ON THE MARKET
    • INTERLEUKIN PRODUCTS
      • TABLE 28: SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPY
    • THERAPEUTIC MONOCLONAL ANTIBODIES
      • TABLE 29: SELECTED APPROVED MONOCLONAL ANTIBODIES
      • TABLE 30: ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONS
  • CANCER VACCINES
    • VACCINES TO PROTECT AGAINST CANCER
    • THERAPEUTIC CANCER VACCINES
      • Melanoma
      • Breast Cancer
      • Cervical Cancer
      • Ovarian Cancer
      • Renal Cell Carcinoma
      • Lung Cancer
      • Pancreatic Cancer
      • Prostate Cancer
        • Sipuleucel-T
        • DCVax-Prostate
  • OTHER IMMUNOTHERAPY PRODUCTS FOR CANCER TREATMENT
    • GLEEVEC
    • IRESSA
    • KYPROLIS
    • NEXAVAR
    • POMALYST
    • SUTENT
    • TARCEVA
    • TYKERB
    • VELCADE
      • TABLE 31: SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTS
  • EXPANDED INFORMATION REGARDING SELECTED CLINICAL TRIALS
    • ROCHE'S MPDL3280A TRIAL
    • AMGEN'S ASPECCT TRIAL
    • SEATTLE GENETICS, MILLENNIUM/TAKEDA TRIAL OF ADCETRIS (NCT01896999)
    • BMS AND ABBVIE'S ELOQUENT-1 AND -2 TRIALS
    • BMS AND NIVOLUMAB WITH OR WITHOUT YERVOY
    • BMS AND YERVOY FOR METASTATIC PROSTATE CANCER
    • MERCK AND LAMBROLIZUMAB (MK-3475)

CHAPTER 5 - ONCOLYTIC VIROTHERAPY

  • VIROTHERAPY
  • ONCOLYTIC VIROLOGY
    • USING HIV TO TREAT CANCER
    • TREATING PEDIATRIC CANCERS WITH VIRUSES
    • CORPORATE DEVELOPMENTS IN ONCOLYTIC VIROLOGY
      • BioVex, Amgen and Talimogene Laherparepvec
      • Oncorine
      • DNX-2401
      • PV701 and Newcastle-Disease Virus (NDV)
      • Picornaviruses
  • NEWS AND DEALS IN CANCER IMMUNOTHERAPY AND VIROLOGY
    • NOVARTIS, UNIVERSITY OF PENNSYLVANIA AND CART TECHNOLOGY
    • CELGENE AND ONCOMED PHARMACEUTICALS
    • SEATTLE GENETICS
    • BRISTOL-MYERS SQUIBB
    • MERCK & CO. AND GSK
    • TAKEDA'S MAB LICENSING DEAL WITH IMMUNOMEDICS
    • GENENTECH/ROCHE AND PERTUZUMAB
    • MERCK KGAA AND STIMUVAX
    • ROCHE AND IMMATICS BIOTECHNOLOGIES GMBH SIGN COLLABORATION DEAL
    • MEDIGENE AG AND TRIANTA IMMUNOTHERAPIES
  • GOVERNMENT REGULATIONS
    • U.S. FOOD AND DRUG ADMINISTRATION
    • FDA AND BREAKTHROUGH THERAPY DESIGNATION (BTD)
    • EUROPEAN REGULATORY AUTHORITIES
    • THE U.K.'S VERSION OF THE FDA'S BTD
  • INDUSTRY STRUCTURE
    • MAJOR COMPANIES AND MARKET SHARE
      • FIGURE 2: MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013 (%)
  • ONCOLYTIC VIROLOGY COMPANIES

CHAPTER 6 - MAJOR MARKETS

  • TABLE 32: GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018 ($ MILLIONS)
  • TABLE 33: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018 ($ MILLIONS)
  • TABLE 34: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018 ($ MILLIONS)
  • TABLE 35: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018 ($ MILLIONS)
  • TABLE 36: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018 ($ MILLIONS)
  • TABLE 37: VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018) ($ MILLIONS)
  • TABLE 38: CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018 ($ MILLIONS)
  • TABLE 39: CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 40: CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 41: CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 42: CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 43: CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 44: CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 45: CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 46: CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 47: CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 48: CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
  • TABLE 49: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018 ($ MILLIONS)
  • TABLE 50: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018 ($ MILLIONS)
  • TABLE 51: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018 ($ MILLIONS)
  • TABLE 52: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018 ($ MILLIONS)
  • TABLE 53: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018 ($ MILLIONS)
  • TABLE 54: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018 ($ MILLIONS)
  • MARKET FOR ONCOLYTIC VIROLOGY PRODUCTS
    • TABLE 55: GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023 ($ MILLIONS)
    • TABLE 56: ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023 ($ MILLIONS)
    • TABLE 57: ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023 ($ MILLIONS)

CHAPTER 7 - TECHNOLOGY

  • PRODUCTION OF MONOCLONAL ANTIBODIES
    • ANTIBODY-DRUG CONJUGATES
    • CAR T-CELL TECHNOLOGY
  • PATENT EVALUATION
    • CANADA AND MONOCLONAL ANTIBODIES
    • INDIA AND (LACK OF) INTELLECTUAL PROPERTY PROTECTION
    • NEWLY ISSUED PATENTS
      • TABLE 58: SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013

CHAPTER 8 - COMPANY PROFILES

  • SELECTED COMPANY PROFILES
    • ABLYNX NV
    • ADURO BIOTECH, INC.
    • ADVAXIS INC.
    • ASTRAZENECA U.S.
    • BRISTOL-MYERS SQUIBB
    • CELGENE CORP.
    • DENDREON CORP.
    • DNATRIX, INC.
    • GENENTECH, A MEMBER OF THE ROCHE GROUP
    • GLAXOSMITHKLINE
    • GLOBEIMMUNE, INC.
    • IMMATICS BIOTECHNOLOGIES GMBH
    • IMMUNOMEDICS, INC.
    • IMMUNOVACCINE, INC.
    • JANSSEN BIOTECH INC./JOHNSON & JOHNSON
    • JENNEREX BIOTHERAPEUTICS INC.
    • MEDIMMUNE LLC (ASTRAZENECA)
    • MEDIVATION INC.
    • MERCK & CO.
    • NORTHWEST BIOTHERAPEUTICS, INC.
    • NOVARTIS INTERNATIONAL AG
    • NOVARTIS PHARMACEUTICALS CORP.
    • ONCOMED PHARMACEUTICALS INC.
    • PFIZER INC.
    • ROCHE (F. HOFFMAN-LA ROCHE AG)
    • VIRALYTICS, LTD.

LIST OF TABLES

  • SUMMARY TABLE CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012
    • TABLE 2: GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012
    • TABLE 3: GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 4: BREAST CANCER INCIDENCE, 2012 (NUMBER)
    • TABLE 5: PROGNOSIS OF BREAST CANCER BASED UPON STAGE (%)
    • TABLE 6: GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
    • TABLE 7: GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
    • TABLE 8: RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCER (%)
    • TABLE 9: GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012 (NUMBER)
    • TABLE 10: AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 11: FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSIS (%)
    • TABLE 12: GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 13: STAGES OF LUNG CANCER
    • TABLE 14: NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGE (%)
    • TABLE 15: GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 16: GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 17: GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012 (THOUSANDS)
    • TABLE 18: EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATE (%)
    • TABLE 19: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 20: U.S. HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 21: CANADIAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 22: EUROPEAN HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 23: JAPANESE HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 24: REST OF WORLD HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • TABLE 25: KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCER
    • TABLE 26: COLONY-STIMULATING FACTORS ON THE MARKET
    • TABLE 27: SELECTED INTERFERON PRODUCTS ON THE MARKET
    • TABLE 28: SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPY
    • TABLE 29: SELECTED APPROVED MONOCLONAL ANTIBODIES
    • TABLE 30: ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONS
    • TABLE 31: SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTS
    • TABLE 32: GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018 ($ MILLIONS)
    • TABLE 34: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018 ($ MILLIONS)
    • TABLE 35: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018 ($ MILLIONS)
    • TABLE 36: VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018 ($ MILLIONS)
    • TABLE 37: VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018) ($ MILLIONS)
    • TABLE 38: CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 40: CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 42: CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 43: CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 44: CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 45: CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 46: CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 47: CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 48: CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 49: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018 ($ MILLIONS)
    • TABLE 50: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 51: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 52: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018 ($ MILLIONS)
    • TABLE 53: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018 ($ MILLIONS)
    • TABLE 54: CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 55: GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023 ($ MILLIONS)
    • TABLE 56: ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023 ($ MILLIONS)
    • TABLE 57: ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023 ($ MILLIONS)
    • TABLE 58: SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013

LIST OF FIGURES

  • SUMMARY FIGURE: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL HUMAN CANCER TRENDS, 2011-2018 (NUMBER OF CASES)
    • FIGURE 2: MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013 (%) 82
Back to Top